Rechallenged mice showed improved survival (one mouse again achieved complete remission) and had higher numbers of tumor-specific (anti-Trp1) CD8+ T cells compared with mice receiving a primary challenge, showing modest evidence of immunologic memory consistent with other IL-2 based therapeutics. Here, CD8A is linked to neoplasm.